Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers

ALBUQUERQUE, New Mexico, March 31 Kingfisher Americas, ahealthcare company focused on improving patient quality of life, announcedtoday that the U.S. Food and Drug Administration (FDA) has granted thecompany 510(k) clearance to market KFH Energy in the United States. Thepatented, high-tech medical device is intended to improve upon quality oflife for sufferers of chronic pain associated with post-polio syndrome,fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, andpatients throughout the United States," said Dr. Henk Snyman, CEO andco-founder of Kingfisher Healthcare, the parent company of KingfisherAmericas. "Our clinical research on post-polio patients yielded dramaticimprovements, and we are eager to address the strong population of chronicpain patients in the U.S. With the proven success of KFH Energy, weanticipate that this technology will be the first in a suite of naturalenergy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy calledBio-Electric Stimulation Therapy (BEST), which is designed to enhance thebody's physiological processes. Intended for home use, KFH Energyencapsulates this novel technology in a hand-held device. Its sleek andmodern design elements, including the patented touch-screen panel, make thedevice both convenient and easy to use. KFH Energy received CE mark in Europein September 2007.

"There is a growing demand among individuals with chronic pain foralternative treatments to improve their condition," said Herb Whitaker, CEOof Kingfisher Americas. "We are excited to have this device available in theStates and are committed to improving the lives of those who have beensidelined as a result of symptoms."

For more information about KFH Energy and its availability in the U.S.,please visit http://www.kfamericas.com or http://www.kfhealth.com.

About Kingfisher Americas

Kingfisher Americas, a subsidiary of the Belgium-based KingfisherHealthcare, is the first company to use safe, non-invasive energy to treatpatients suffering from chronic conditions. It utilizes a technology platformcalled BEST (Bio-Electric Stimulation Therapy) from which unique products aredeveloped by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico,Kingfisher Americas focuses on establishing relationships with patients,patient support groups, and medical experts to improve the quality of life offibromyalgia, post polio, and chronic fatigue syndrome patients. For moreinformation, please visit http://www.kfamericas.com.

SOURCE Kingfisher Americas

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...